Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

被引：7
|
作者：
Chi, Kim N. [1 ]
Fleshner, Neil [2 ]
Chiuri, Vincenzo Emanuele [3 ]
Van Bruwaene, Siska [4 ]
Hafron, Jason [5 ]
McNeel, Douglas G. [6 ]
De Porre, Peter [7 ]
Maul, Raymond Scott [8 ]
Daksh, Mahesh [9 ]
Zhong, Xiaogang [10 ]
Mason, Gary E. [11 ]
Tutrone, Ronald F. [12 ]
机构：
[1] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] I Veris Delli Ponti Hosp, Lecce, Italy
[4] AZ Groeninge Hosp, Dept Urol, Kortrijk, Belgium
[5] Michigan Inst Urol, W Bloomfield, MI USA
[6] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[7] Janssen Res & Dev, Beerse, Belgium
[8] Janssen Res & Dev, Los Angeles, CA USA
[9] Janssen Res & Dev, Raritan, NJ USA
[10] Janssen Res & Dev, College Pk, MD USA
[11] Janssen Res & Dev, Spring House, PA USA
[12] Chesapeake Urol Res Assoc, Towson, MD USA
来源：
ONCOLOGIST | 2023年 / 28卷 / 05期
关键词：
castration-resistant prostate cancer; PARP inhibitor; homologous recombination repair; niraparib; abiraterone acetate;
D O I：
10.1093/oncolo/oyad008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.
引用
收藏
页码：E309 / E312
页数：4
相关论文
共 50 条
  • [21] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
    Danila, Daniel C.
    Morris, Michael J.
    de Bono, Johann S.
    Ryan, Charles J.
    Denmeade, Samuel R.
    Smith, Matthew R.
    Taplin, Mary-Ellen
    Bubley, Glenn J.
    Kheoh, Thian
    Haqq, Christopher
    Molina, Arturo
    Anand, Aseem
    Koscuiszka, Michael
    Larson, Steve M.
    Schwartz, Lawrence H.
    Fleisher, Martin
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1496 - 1501
  • [23] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
    K. N. Chi
    A. Tolcher
    P. Lee
    P. J. Rosen
    C. K. Kollmannsberger
    K. P. Papadopoulos
    A. Patnaik
    A. Molina
    J. Jiao
    C. Pankras
    B. Kaiser
    A. Bernard
    N. Tran
    M. Acharya
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 237 - 244
  • [25] Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Tolcher, A.
    Lee, P.
    Rosen, P. J.
    Kollmannsberger, C. K.
    Papadopoulos, K. P.
    Patnaik, A.
    Molina, A.
    Jiao, J.
    Pankras, C.
    Kaiser, B.
    Bernard, A.
    Tran, N.
    Acharya, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 237 - 244
  • [26] Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors
    Romero, Miguel E. jimenez
    Gallego, Maria Camacho
    Serrato, Jose c. navarro
    Sanchez Hurtado, Miguel A.
    Santotoribio, Jose D.
    ANTICANCER RESEARCH, 2021, 41 (08) : 3955 - 3968
  • [27] The economics of abiraterone acetate for castration-resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios G.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) : 175 - 179
  • [28] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Salem, Mohamed
    Garcia, Jorge A.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 92 - 96
  • [29] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Mohamed Salem
    Jorge A. Garcia
    Current Oncology Reports, 2011, 13 : 92 - 96
  • [30] Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Lily P. H. Yang
    Katherine A. Lyseng-Williamson
    Drugs & Aging, 2012, 29 : 243 - 248
12345